Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine
Authors:
- Chin-Fen YangCYChin-Fen Yang
- C. Kathy WangCWC. Kathy Wang
- Elissa MalkinEMElissa Malkin
- Jeanne H. SchickliJSJeanne H. Schickli
- Cindy ShambaughCSCindy Shambaugh
- Fengrong ZuoFZFengrong Zuo
- Mark S. GalinskiMGMark S. Galinski
- Filip DubovskyFDFilip Dubovsky
- Roderick S. TangRTRoderick S. Tang
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young childrenVaccine, 2012
- Phase 1 Study of the Safety and Immunogenicity of a Live, Attenuated Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Vaccine in Seronegative ChildrenThe Pediatric Infectious Disease Journal, 2012
- Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at preventionAdvances in Therapy, 2011
- Respiratory Syncytial Virus: A Prioritized or Neglected Target?Future Medicinal Chemistry, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- Challenges in developing a pediatric RSV vaccineHuman Vaccines, 2009
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- A Bovine Parainfluenza Virus Type 3 Vaccine Is Safe and Immunogenic in Early InfancyThe Journal of Infectious Diseases, 2005
- Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodiesVaccine, 2003
- Expression of the Surface Glycoproteins of Human Parainfluenza Virus Type 3 by Bovine Parainfluenza Virus Type 3, a Novel Attenuated Virus Vaccine VectorJournal of Virology, 2000